Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernanda Ludolf

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Cytokine|February 12, 2023
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasisCamila S Freitas, Daniela P Lage, Amanda S Machado, et al.
Acta Tropica|March 20, 2022
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantumAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Parasitology International|July 31, 2019
A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasisJessica K T Sousa, Luciana M R Antinarelli, Débora V C Mendonça, et al.
Molecular Immunology|December 31, 2018
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infectionPatrícia A F Ribeiro, Daniel S Dias, Daniela P Lage, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
Parasitology Research|September 28, 2023
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasisMarcelo M Jesus, Daniela P Lage, Danniele L Vale, et al.
Parasite Immunology|April 19, 2022
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasisAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Molecular Immunology|February 2, 2023
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasisDaniela P Lage, Amanda S Machado, Camila S Freitas, et al.
Molecular Immunology|October 17, 2020
Corrigendum to "Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis". Molecular Immunology 124 (2020) 161-171João A Oliveira-da-Silva, Daniela P Lage, Fernanda F Ramos, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Cytokine|February 12, 2023
Exploring drug repositioning for leishmaniasis treatment: Ivermectin plus polymeric micelles induce immunological response and protection against tegumentary leishmaniasisCamila S Freitas, Daniela P Lage, Amanda S Machado, et al.
Acta Tropica|March 20, 2022
A recombinant Leishmania amastigote-specific protein, rLiHyG, with adjuvants, protects against infection with Leishmania infantumAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Parasitology International|July 31, 2019
A chloroquinoline derivate presents effective in vitro and in vivo antileishmanial activity against Leishmania species that cause tegumentary and visceral leishmaniasisJessica K T Sousa, Luciana M R Antinarelli, Débora V C Mendonça, et al.
Molecular Immunology|December 31, 2018
Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infectionPatrícia A F Ribeiro, Daniel S Dias, Daniela P Lage, et al.
Experimental Parasitology|December 18, 2020
Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasisThiago A R Reis, João A Oliveira-da-Silva, Grasiele S V Tavares, et al.
Parasitology Research|September 28, 2023
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasisMarcelo M Jesus, Daniela P Lage, Danniele L Vale, et al.
Parasite Immunology|April 19, 2022
Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasisAmanda S Machado, Daniela P Lage, Danniele L Vale, et al.
Molecular Immunology|February 2, 2023
Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasisDaniela P Lage, Amanda S Machado, Camila S Freitas, et al.
Molecular Immunology|October 17, 2020
Corrigendum to "Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis". Molecular Immunology 124 (2020) 161-171João A Oliveira-da-Silva, Daniela P Lage, Fernanda F Ramos, et al.
Experimental Parasitology|March 21, 2024
Treatment using vanillin-derived synthetic molecules incorporated into polymeric micelles is effective against infection caused by Leishmania amazonensis speciesIsabela A G Pereira, Camila S Freitas, Raquel S B Câmara, et al.
Pageof 8